Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized ...
Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...
Outcomes of concurrent chemo-radiotherapy (CCRT) in locally advanced cervical cancer (LACC). Results of a retrospective analysis of a single institution No significant financial relationships to ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m 2) every 3 weeks or ...
Investigators evaluated whether the addition of carboplatin to neoadjuvant chemotherapy improved efficacy outcomes in patients with early-stage TNBC.
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — The addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy ...
The buzz created by two phase III studies testing immunotherapy in advanced or recurrent endometrial cancer at the Society of Gynecologic Oncology (SGO) annual meeting in April carried over to the ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kevin Kalinsky, MD ...
Researchers at Baylor College of Medicine and the Broad Institute of MIT and Harvard and clinicians at Washington University in St. Louis have identified biological markers in triple negative breast ...
Cancer drug shortages deliver ‘gut punch’ to patients unsure if their survival odds will be undercut
Mairéad McInerney will never know if changes in her treatment plan have undercut her odds of surviving stage 3 triple-negative breast cancer. Critical shortages in cancer drugs have forced her to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback